JPWO2022221440A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022221440A5 JPWO2022221440A5 JP2023563063A JP2023563063A JPWO2022221440A5 JP WO2022221440 A5 JPWO2022221440 A5 JP WO2022221440A5 JP 2023563063 A JP2023563063 A JP 2023563063A JP 2023563063 A JP2023563063 A JP 2023563063A JP WO2022221440 A5 JPWO2022221440 A5 JP WO2022221440A5
- Authority
- JP
- Japan
- Prior art keywords
- mrna
- vaccine
- antigenic polypeptide
- encoding
- influenza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000700605 Viruses Species 0.000 claims 13
- 229960005486 vaccine Drugs 0.000 claims 12
- 230000000890 antigenic effect Effects 0.000 claims 9
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 230000000241 respiratory effect Effects 0.000 claims 9
- 108700026244 Open Reading Frames Proteins 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- -1 amino lipid Chemical class 0.000 claims 5
- 150000002632 lipids Chemical class 0.000 claims 5
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 claims 4
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 4
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 claims 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 4
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims 2
- UVBYMVOUBXYSFV-UHFFFAOYSA-N 1-methylpseudouridine Natural products O=C1NC(=O)N(C)C=C1C1C(O)C(O)C(CO)O1 UVBYMVOUBXYSFV-UHFFFAOYSA-N 0.000 claims 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims 2
- 101710154606 Hemagglutinin Proteins 0.000 claims 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 2
- 101710176177 Protein A56 Proteins 0.000 claims 2
- 229960005305 adenosine Drugs 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims 2
- 229940029575 guanosine Drugs 0.000 claims 2
- 239000000185 hemagglutinin Substances 0.000 claims 2
- 206010022000 influenza Diseases 0.000 claims 2
- 208000037797 influenza A Diseases 0.000 claims 2
- 208000037798 influenza B Diseases 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 125000003835 nucleoside group Chemical group 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 229920002477 rna polymer Polymers 0.000 claims 2
- 241000712461 unidentified influenza virus Species 0.000 claims 2
- 206010062106 Respiratory tract infection viral Diseases 0.000 claims 1
- 229930182558 Sterol Natural products 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 229940125904 compound 1 Drugs 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 150000003432 sterols Chemical class 0.000 claims 1
- 235000003702 sterols Nutrition 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163175007P | 2021-04-14 | 2021-04-14 | |
| US63/175,007 | 2021-04-14 | ||
| US202163242346P | 2021-09-09 | 2021-09-09 | |
| US63/242,346 | 2021-09-09 | ||
| PCT/US2022/024669 WO2022221440A1 (en) | 2021-04-14 | 2022-04-13 | Influenza-coronavirus combination vaccines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024513999A JP2024513999A (ja) | 2024-03-27 |
| JP2024513999A5 JP2024513999A5 (https=) | 2025-04-21 |
| JPWO2022221440A5 true JPWO2022221440A5 (https=) | 2025-04-21 |
Family
ID=81579694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023563063A Pending JP2024513999A (ja) | 2021-04-14 | 2022-04-13 | インフルエンザ－コロナウイルス組み合わせワクチン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240226277A1 (https=) |
| EP (1) | EP4322994A1 (https=) |
| JP (1) | JP2024513999A (https=) |
| AU (1) | AU2022258463A1 (https=) |
| WO (1) | WO2022221440A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201912038TA (en) | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
| WO2017020026A1 (en) | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Concatemeric peptide epitopes rnas |
| EP3364949A4 (en) | 2015-10-22 | 2019-07-31 | ModernaTX, Inc. | CANCER VACCINES |
| TW201729835A (zh) | 2015-10-22 | 2017-09-01 | 現代公司 | 呼吸道病毒疫苗 |
| MA45052A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille |
| CN116837052A (zh) | 2016-09-14 | 2023-10-03 | 摩登纳特斯有限公司 | 高纯度rna组合物及其制备方法 |
| WO2018089851A2 (en) | 2016-11-11 | 2018-05-17 | Modernatx, Inc. | Influenza vaccine |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018187590A1 (en) | 2017-04-05 | 2018-10-11 | Modernatx, Inc. | Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| ES2983060T3 (es) | 2017-08-18 | 2024-10-21 | Modernatx Inc | Variantes de ARN polimerasa |
| WO2019036683A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | ANALYTICAL METHODS BY HPLC |
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
| AU2019345067A1 (en) | 2018-09-19 | 2021-04-08 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| MA53650A (fr) | 2018-09-19 | 2021-07-28 | Modernatx Inc | Lipides peg et leurs utilisations |
| CN113271926A (zh) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | 脂质纳米颗粒的制备及其施用方法 |
| CN113795579A (zh) | 2019-02-20 | 2021-12-14 | 摩登纳特斯有限公司 | 用于共转录加帽的rna聚合酶变体 |
| CA3132975A1 (en) | 2019-03-11 | 2020-09-17 | Modernatx, Inc. | Fed-batch in vitro transcription process |
| EP3938379A4 (en) | 2019-03-15 | 2023-02-22 | ModernaTX, Inc. | Hiv rna vaccines |
| US12329811B2 (en) | 2021-01-11 | 2025-06-17 | Modernatx, Inc. | Seasonal RNA influenza virus vaccines |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| EP4604995A1 (en) * | 2022-10-17 | 2025-08-27 | BioNTech SE | Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection |
| AU2024270076A1 (en) * | 2023-05-10 | 2025-11-27 | Seqirus Inc. | Combination vaccine |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE490267T1 (de) | 2001-06-05 | 2010-12-15 | Curevac Gmbh | Stabilisierte mrna mit erhöhtem g/c-gehalt, kodierend für ein virales antigen |
| US9012219B2 (en) | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| US8278063B2 (en) | 2007-06-29 | 2012-10-02 | Commonwealth Scientific And Industrial Research Organisation | Methods for degrading toxic compounds |
| DK2205618T3 (en) | 2007-09-26 | 2017-02-20 | Intrexon Corp | SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION |
| WO2009075886A1 (en) | 2007-12-11 | 2009-06-18 | The Scripps Research Institute | Compositions and methods related to mrna translational enhancer elements |
| PL3586861T3 (pl) | 2011-06-08 | 2022-05-23 | Translate Bio, Inc. | Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna |
| US10245229B2 (en) | 2012-06-08 | 2019-04-02 | Translate Bio, Inc. | Pulmonary delivery of mRNA to non-lung target cells |
| US10130649B2 (en) | 2013-03-15 | 2018-11-20 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| SG11201510747RA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Method for increasing expression of rna-encoded proteins |
| ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
| KR102399799B1 (ko) | 2013-12-30 | 2022-05-18 | 큐어백 아게 | 인공 핵산 분자 |
| CA2927254C (en) | 2013-12-30 | 2023-10-24 | Curevac Ag | Artificial nucleic acid molecules |
| TW201729835A (zh) * | 2015-10-22 | 2017-09-01 | 現代公司 | 呼吸道病毒疫苗 |
| EP3405579A1 (en) | 2016-01-22 | 2018-11-28 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| ES2983060T3 (es) | 2017-08-18 | 2024-10-21 | Modernatx Inc | Variantes de ARN polimerasa |
| CN113795579A (zh) | 2019-02-20 | 2021-12-14 | 摩登纳特斯有限公司 | 用于共转录加帽的rna聚合酶变体 |
| WO2021237174A1 (en) * | 2020-05-21 | 2021-11-25 | Vaxess Technologies, Inc. | Compositions and devices for vaccine release and uses thereof |
| MX2022015132A (es) * | 2020-05-29 | 2023-03-08 | CureVac SE | Vacunas combinadas a base de acidos nucleicos. |
| GB2596820A (en) * | 2020-07-07 | 2022-01-12 | Spicona Inc | Combination vaccine |
| CN112546211A (zh) * | 2020-10-23 | 2021-03-26 | 嘉晨西海(杭州)生物技术有限公司 | 基于mRNA的针对冠状病毒和流感病毒的联合疫苗及其制备方法 |
-
2022
- 2022-04-13 JP JP2023563063A patent/JP2024513999A/ja active Pending
- 2022-04-13 EP EP22720863.4A patent/EP4322994A1/en active Pending
- 2022-04-13 AU AU2022258463A patent/AU2022258463A1/en active Pending
- 2022-04-13 WO PCT/US2022/024669 patent/WO2022221440A1/en not_active Ceased
- 2022-04-13 US US18/555,130 patent/US20240226277A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022221440A5 (https=) | ||
| JPWO2022221335A5 (https=) | ||
| JPWO2022155524A5 (https=) | ||
| Fougeroux et al. | Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity | |
| TW202140518A (zh) | 冠狀病毒疫苗 | |
| JPWO2022155530A5 (https=) | ||
| JP5331340B2 (ja) | インフルエンザウィルスワクチン組成物、及びその使用方法 | |
| Song et al. | Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus | |
| TW202233232A (zh) | 遞送mRNA疫苗的脂質奈米顆粒 | |
| Verwey et al. | Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus: C. Verwey, SA Madhi | |
| TW202206096A (zh) | 冠狀病毒疫苗 | |
| US20230416309A1 (en) | Fusion protein and application thereof | |
| Melero et al. | The Pneumovirinae fusion (F) protein: A common target for vaccines and antivirals | |
| JPH11500409A (ja) | ワクチン組成物用アジュバント | |
| Fotouhi et al. | Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus | |
| Ibañez et al. | M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A | |
| RU2015132962A (ru) | Иммуногенные композиции на основе вируса гриппа и их применение | |
| JP2011504486A5 (https=) | ||
| RU2014104094A (ru) | Катионные эмульсии масло-в-воде | |
| TW202333780A (zh) | 冠狀病毒疫苗 | |
| Ebrahimi et al. | In contrast to conventional inactivated influenza vaccines, 4xM2e. HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran | |
| JP2014522841A5 (https=) | ||
| JP2009539965A5 (https=) | ||
| TW201427686A (zh) | 改良之疫苗組成物及使用方法 | |
| Bellier et al. | Virus-like particle-based vaccines against hepatitis C virus infection |